Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Megna

Showing results (1-10 of 381) with videos related to

Pageof 39
Sort By:
Clinical and Experimental Dermatology|October 7, 2024
The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis)Matteo Megna
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Hidradenitis suppurativa and bimekizumab: Looking to the futureFabrizio Martora, Matteo Megna
Clinical, Cosmetic and Investigational Dermatology|December 26, 2025
Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published LiteratureFabrizio Martora, Matteo Megna
Journal of the European Academy of Dermatology and Venereology : JEADV|October 2, 2025
Reply to 'Rifampicin and clindamycin for epidermal growth factor receptor inhibitor-related acneiform rash'Fabrizio Martora, Matteo Megna
Expert Opinion on Drug Safety|September 25, 2025
Definition of treatment resistant psoriasis and related safety concernsMatteo Megna, Luca Potestio
Dermatology Reports|March 6, 2025
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasisPaolo Dapavo, Matteo Megna, Marina Talamonti
Medical Hypotheses|July 30, 2020
Holistic approach to psoriasis patient: What about epicardial fat tissue?Eleonora Cinelli, Gabriella Fabbrocini, Matteo Megna
International Journal of Dermatology|July 26, 2020
Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?Matteo Megna, Gabriella Fabbrocini, Claudio Marasca
Journal of the American Academy of Dermatology|February 16, 2025
Response to Sood et al's "Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"Luca Potestio, Fabrizio Martora, Matteo Megna
Medical Hypotheses|April 28, 2020
May IL-17 have a role in COVID-19 infection?Matteo Megna, Maddalena Napolitano, Gabriella Fabbrocini
Pageof 39

Showing results (1-10 of 381) with videos related to

Sort By:
Pageof 39
Clinical and Experimental Dermatology|October 7, 2024
The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis)Matteo Megna
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Hidradenitis suppurativa and bimekizumab: Looking to the futureFabrizio Martora, Matteo Megna
Clinical, Cosmetic and Investigational Dermatology|December 26, 2025
Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published LiteratureFabrizio Martora, Matteo Megna
Journal of the European Academy of Dermatology and Venereology : JEADV|October 2, 2025
Reply to 'Rifampicin and clindamycin for epidermal growth factor receptor inhibitor-related acneiform rash'Fabrizio Martora, Matteo Megna
Expert Opinion on Drug Safety|September 25, 2025
Definition of treatment resistant psoriasis and related safety concernsMatteo Megna, Luca Potestio
Dermatology Reports|March 6, 2025
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasisPaolo Dapavo, Matteo Megna, Marina Talamonti
Medical Hypotheses|July 30, 2020
Holistic approach to psoriasis patient: What about epicardial fat tissue?Eleonora Cinelli, Gabriella Fabbrocini, Matteo Megna
International Journal of Dermatology|July 26, 2020
Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?Matteo Megna, Gabriella Fabbrocini, Claudio Marasca
Journal of the American Academy of Dermatology|February 16, 2025
Response to Sood et al's "Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"Luca Potestio, Fabrizio Martora, Matteo Megna
Medical Hypotheses|April 28, 2020
May IL-17 have a role in COVID-19 infection?Matteo Megna, Maddalena Napolitano, Gabriella Fabbrocini
Pageof 39